CClinicalTrials.gg
CompletedNCT01271842RESPIFLUUpdated Oct 7, 2025

Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study

An observational study in Influenza, Pneumonia, Viral and Pulmonary Fibrosis, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
38
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Influenza A (H1N1) v2009 infection was responsible throughout the world of viral pneumonia and severe pulmonary edema requiring rescue therapeutics such as extracorporeal oxygenation. To date, no data exist on the outcome of patients having developed acute respiratory distress syndrome (ARDS) due to influenza A (H1N1) v2009, and in particular in patients with very severe lung injury requiring extracorporeal oxygenation. Although data exist on long-term outcome of survivors of ARDS, the patients included in the observational studies were heterogeneous with various underlying disease. Moreover, no study compared the outcome of survivors of ARDS according to the need or not of extracorporeal oxygenation. We therefore conducted this prospective case-control study to compare the long term pulmonary and extra pulmonary function in 2 groups of patients, one with severe ARDS due to H1N1 requiring extracorporeal oxygenation (case), and the second with ARDS due to H1N1 but without need for extracorporeal oxygenation (control). Eighteen case patients with inclusion and without non-inclusion criteria were selected from our national registry, and 32 controls (with inclusion and exclusion criteria) were matched on age, sex, and body mass index. All 48 patients will be contacted and asked to participate. Patients will be evaluate at least 9 months after ICU discharge, looking for health-related quality of life, measured by the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36), post traumatic stress disorder, assessed by the Impact of Event Scale Anxiety, and depression, assessed by the Hospital and Depression Score. Pulmonary function testing, including VO2 max test on a static bike will be performed. Muscle weakness will be clinically evaluated by the medical council research (MRC) test, with an additional electromyography if the result of the test was \<48/60. A CT-scan will be performed, looking for lung abnormalities (fibrosis...). Albumin and prealbumin will be measured to evaluate the nutritional status.

Primary outcome measurement is carbon monoxide diffusion capacity. The primary hypothesis is that patients with extracorporeal oxygenation will have a carbon monoxide diffusion capacity lower than patients without extracorporeal oxygenation (15% difference between groups). Inclusion of 13 patients in the case group and 26 patients in the control group will allow testing this hypothesis with a statistical power of 80% (standard deviation 15%). Secondary outcome measures will be the quality of life, the presence or not of post-traumatic stress disorders, of anxiety and/or depression, the results of pulmonary function testing, of the CT-scan, and of muscle testing. All results will be compared in patients with and without extracorporeal oxygenation.

02

Conditions studied

  • Influenza
  • Pneumonia, Viral
  • Pulmonary Fibrosis
  • Quality of Life
  • Stress Disorders, Post Traumatic
03

In context

Influenza, Human

2,214 studies on the registry are indexed under Influenza, Human; 163 are open to participants now.

This study's enrollment of 38 is below the median of 300 across 305 observational studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Two groups of survivors of severe acute respiratory distress syndrome due to influenza A H1N1 infection will be recruited; the first required extracorporeal oxygenation at the time of viral infection, and the second did not require extracorporeal oxygenation at the time of viral infection. Patients will be recruited at least 9 months after ICU discharge. Eighteen case patients matching inclusion and non-inclusion criteria were selected from our national registry, and 32 controls (with inclusion and exclusion criteria) were matched on age, sex, and body mass index.

Inclusion criteria

  • Patients from 18 to 65 year-old
  • Survivors of ARDS due to influenza A (H1N1) v2009 infection developed during the winter 2009-2010
  • Influenza A (H1N1) infection confirmed by RT-PCR
  • Written consent
  • Need or not for extra corporeal lung oxygenation

Exclusion criteria

Exclusion Criteria:

  • Pre existing pulmonary disease
  • Asthma
  • Diabetes mellitus
  • Immunodepression
  • Cancer
  • Severe obesity (BMI >35 kg/m²)
  • Neuromuscular disease
  • Pre existing cardiac disease
  • Chronic renal failure
  • Liver failure
  • Stroke
  • Pregnancy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
38 participants (actual)

Groups and cohorts

  • Extra corporeal oxygenation

    Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection

  • No extracorporeal oxygenation

    Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection

06

What researchers measure

Primary outcomes

  1. Carbon monoxide diffusion capacity

    Time frame: At least 9 months after ICU discharge

Secondary outcomes

  1. Health-related quality of life

    Time frame: At least 9 months after ICU discharge

  2. Pulmonary function testing

    Time frame: At least 9 months after ICU discharge

  3. Post traumatic stress disorder

    Time frame: At least 9 months after ICU discharge

  4. Anxiety and depression

    Time frame: At least 9 months after ICU discharge

  5. Muscle weakness

    Time frame: At least 9 months after ICU discharge

  6. Lung abnormalities on CT scan

    Time frame: At least 9 months after ICU discharge

  7. Alveoli-arterial gradient of oxygen during effort

    Time frame: At least 9 months after ICU discharge

07

Study locations

1 site
  • CHU Pitié-Salpêtrière
    Paris, 75013, France
08

References and documents

Publications

  • Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196. PubMed 22948576 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01271842
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Oct 2010
Primary completion
Oct 2, 2011
Completion
Oct 2, 2011
Last update
Oct 7, 2025

Study contacts

Charles-Edouard Luyt, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion